Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections.
Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections.
复制标题
儿科肿瘤患者败血症：草绿色链球菌感染的意义。
DOI：
--
复制
发表时间：
1990
影响因子：
45.3
通讯作者：
J. Quinn
中科院分区：
文献类型：
--
作者：
S. Weisman;F. Scoopo;G. Johnson;A. Altman;J. Quinn
对61例恶性肿瘤患儿的109例连续败血症发作进行了回顾性评价。此外，还审查了接受大剂量阿糖胞苷（HDAC）化疗的所有儿科肿瘤患者的记录。革兰氏阳性菌占败血症发作的82.6%。在总组中，凝固酶阴性葡萄球菌和草绿色链球菌分别占35.8%和28.4%。在粒细胞减少症患者中，草绿色链球菌是最常见的病原体（36.8%）。在接受HDAC的患者亚组中，62.5%的败血症发作是由草绿色链球菌引起的。在草绿色链球菌败血症的总病例中，有9例（29%）发生了肺部并发症，而这些并发症仅发生在由其他生物体引起的败血症发作中的8例（10.3%）。在草绿色败血症患者中，既往接受HDAC治疗不会增加肺部并发症的发生率。我们的研究结果表明，在恶性肿瘤的败血症儿童中，革兰氏阳性菌的发病率很高，包括草绿色链球菌，它们曾被认为是培养污染物。
One hundred nine consecutive episodes of septicemia were retrospectively evaluated in 61 children with malignancy. In addition, the records of all pediatric oncology patients who received high-dose cytarabine (HDAC) chemotherapy were reviewed. Gram-positive organisms accounted for 82.6% of the septicemic episodes. In the total group, coagulase-negative staphylococci and viridans streptococci accounted for 35.8% and 28.4% of the episodes, respectively. In granulocytopenic patients, viridans streptococci were the most common pathogens (36.8%). In the subset of patients who received HDAC, 62.5% of the septicemic episodes were caused by viridans streptococci. Pulmonary complications developed in nine (29%) of the total cases of viridans streptococcal sepsis, whereas these complications occurred in only eight (10.3%) of the septic episodes caused by other organisms. In patients who had viridans septicemia, prior treatment with HDAC did not increase the incidence of pulmonary complications. In septic children with malignancy, our results demonstrate a high incidence of gram-positive organisms, including viridans streptococci, which were once regarded as culture contaminants.
持续输注大剂量阿糖胞苷治疗难治性儿童白血病。
DOI：
10.1200/jco.1984.2.10.1092
发表时间：
1984
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Ochs,J;Sinkule,JA;Danks,MK;Look,AT;Bowman,WP;Rivera,G
通讯作者：
Rivera,G
高剂量 1-β-D-阿拉伯呋喃糖基胞嘧啶治疗急性白血病和难治性淋巴瘤的初步研究：临床反应和药理学。
影响因子：
11.2
作者：
Early,AP;Preisler,HD;Slocum,H;Rustum,YM
通讯作者：
Rustum,YM
DOI：
10.1001/archpedi.1984.02140460007005
发表时间：
1984-01-01
影响因子：
--
作者：
FRIEDMAN, LE;BROWN, AE;ARMSTRONG, D
通讯作者：
ARMSTRONG, D